Detalhe da pesquisa
1.
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
BMC Cancer
; 16(1): 780, 2016 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27724870
2.
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
J Geriatr Oncol
; 14(1): 101372, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36127284
3.
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Sci Rep
; 13(1): 3705, 2023 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879012
4.
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Eur J Cancer
; 51(10): 1212-20, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25892646